HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.